drugset / Trial / NCT04374370

SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)

NCT04374370 ↗

Expanded access No longer available AdventHealth

Summary

Convalescent plasma has been administered to treat different infectious diseases previously with some success. There is currently no approved and proven treatment options available for the novel coronavirus disease (COVID-19 virus). Some early data has shown a potential benefit in treating hospitalized patients who have tested positive for COVID-19 with convalescent plasma infusions of fresh plasma donated by fully recovered COVID-19 patients. The antibodies present in the recovered patients' plasma may be of benefit in helping critically ill and infected patients recover from the COVID-19 virus.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject SARS-CoV-2 convalescent plasma Protein / enzyme biologic — —

Indications